Najít Technologies Inc. is focused on developing innovative vaccines targeting a range of infectious diseases that pose significant global health challenges. The company employs its proprietary HydroVax platform, which enhances the safety and efficacy of vaccine candidates. This platform is complemented by a Vero cell Master Cell Bank (MCB) and a Working Cell Bank (WCB), both produced under current Good Manufacturing Practice (cGMP) compliance. Najít Technologies has optimized virus growth conditions and purification strategies, allowing for the efficient manufacturing of various vaccine candidates, including those for West Nile Virus, Yellow Fever Virus, Dengue Virus, Chikungunya Virus, Zika Virus, and Campylobacter.

A key strength of Najít Technologies lies in the adaptability of its vaccine platform, which enables the rapid addition of new vaccine targets to its product pipeline. The company is also open to collaborations with industry and academic partners to further develop human and veterinary vaccine products. These partnerships may involve co-development agreements, marketing and distribution arrangements, or sub-licensing opportunities, all aimed at maximizing the potential of their advanced vaccine technologies.

United States

Najít Technologies is dedicated to the development of safe and effective vaccines against infectious diseases of global importance.

Najit Technologies Inc

Company Details